When integrated with sPD-L1 levels, indicative of immune evasion [9], these biomarkers collectively may offer an in-depth perspective on tumor biology, immune response dynamics, and the heterogeneity of prostate cancer, supporting improved diagnostic and therapeutic strategies. This evidence concerns the gene SPDL1 and prostate carcinoma.